Friday 1st September 2017: Juno Pharmaceuticals today announced it has acquired the Amneal injectables, ophthalmic, and oncology portfolio. This business primarily has a focus on Australian hospital customers. “Juno is excited to add the Amneal Australia’s hospital injectable, ophthalmic, and oncology range to its growing portfolio. The Amneal range complements many of the current Juno … Continue reading Amneal Portfolio AcquisitionRead More..
MELBOURNE, AUSTRALIA–Celgene Pty Ltd and Juno Pharmaceuticals Pty Ltd today announced the signing of a definitive agreement in which Celgene has appointed Juno as its strategic partner for its maturing brand – Vidaza® in Australia. Under the terms of the agreement, Juno will assist with the commercial management of Vidaza® in Australia. “By combining forces … Continue reading Juno Pharmaceuticals appointed by Celgene Pty as Strategic Partner for its maturing brand Vidaza® (5-azacitidine) in AustraliaRead More..
Juno Pharmaceuticals is excited to announced it has been appointed as the exclusive distributor in Australia and New Zealand for Hexvix® (hexaminolevulinate hydro-chloride), an innovative breakthrough technology to aid in the diagnosis and management of non-muscle-invasive bladder cancer. The registration process will begin immediately and it is hoped that this product will be registered in 2016 In Australia, each … Continue reading Juno Appointed Exclusive Distributor for Hexvix®Read More..
Juno Pharmaceuticals is pleased to announce the TGA granted approval for the following Category 1 New Generic Medicine application in March 2015: TRANEXAMIC ACID JUNO tranexamic acid 500mg/5mL and 1000mg/10mL solution for injection ampoule was listed on the ARTG on, 02 March 2015. Presented in a clear glass ampoule with a shelf life of 2 … Continue reading New Generic Medicine Approval for Tranexamic Acid JunoRead More..
Juno Pharmaceuticals is pleased to announce the TGA granted approval for the following Medical Device Class 3 application in February 2015: iAluRil Procedure Pack. iAluRil prefill contains: 800 mg/50 ml sodium hyaluronate (1.6%) and 1 g /50 ml sodium chondroitin sulfate (2%). iAluRil is indicated to re-establish the glycosaminoglycan layers (GAGs) of the urothelial vesical tissue in cases … Continue reading Medical Device ApprovalRead More..
Juno Pharmaceuticals is pleased to announce the TGA granted approval for the following Category 1 New Generic Medicine applications in 2014: TIROFIBAN AC tirofiban (as hydrochloride) 12.5mg/50mL Concentrated Injection for infusion on 09 May 2014. Presented in a clear glass vial with a shelf life of 3 years, TIROFIBAN AC, in combination with heparin, is … Continue reading Two New Generic Medicine ApprovalsRead More..